Multaq dronedarone: Additional Phase III data

A post hoc subgroup analysis of 154 patients from the Phase III European EURIDIS and international ADONIS trials who received Multaq or placebo within 2 days of discontinuing treatment with amiodarone showed that Multaq significantly reduced AF or atrial flutter recurrence vs. placebo (p=0.022). The rate of serious adverse events was low and similar across both groups with no episodes of torsades de pointes reported. Multaq-treated patients did experience more bradyarrhythmic events and a higher rate of drug discontinuation due to QTc-prolongations vs. placebo (3.1% vs. 0% and 7.9% va. 3.6%, respectively). Data were presented at the American College of Cardiology meeting in Atlanta. ...